

Rhythm Biosciences Contracts with Nutripath on Automation Agreement

Highlights

- ✓ **Automation project for ColoSTAT® kit commences on laboratory diagnostic machine Tecan EVO; and**
- ✓ **Objective is to reduce manual handling, costs, complexity of processes and improve efficiency to obtaining a result.**

As per 31 July (Appendix 4C), transformative cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: RHY) ("**Rhythm**" or the "**Company**") is pleased to confirm it has progressed the Company's objective to automate the ColoSTAT® test ("**ColoSTAT**" or the "**Kit**") and transfer the immunoassay procedure and protocol to its first automated system.

Automation objectives

ColoSTAT is an ELISA based testing platform (utilising five different protein biomarkers) which requires manual handling in the laboratory process for preparing the immunoassay.

Collaborating with Nutripath Pty Ltd ("**Nutripath**") and one of its diagnostic machine vendors, Tecan Australia Pty Ltd (a subsidiary of Swiss based Tecan Group Ltd) ("**Tecan**"), the parties identified opportunities to streamline the current process using the Tecan EVO. The Tecan EVO is widely used throughout the current Rhythm target markets (UK, Europe, Australia, New Zealand, Asia, and the USA) for ELISA immunoassay testing.

Automation Agreement with Nutripath Pty Ltd

Rhythm has executed an Automation Agreement with Melbourne-based, privately owned medical laboratory, Nutripath Pty Ltd. Established in 2011, Nutripath is a specialty clinical laboratory, pioneering a systems approach that supports healthcare providers in the area of health and wellbeing pathology testing. Nutripath's testing services assist general practitioners and other healthcare providers in identifying the underlying cause of illness, as well as providing tools for the prevention of disease and premature ageing. Nutripath has NATA ISO15189 accreditation, a requirement for quality and competence in medical laboratories.

Nutripath has established a broad reach in the Asia Pacific region, with current business channels in New Zealand, the Pacific Islands and South-East Asia. With a significant growth in providing the private market with specialty tests, Nutripath has also increased their footprint into the USA via a CLIA lab, offering an opportunity for global marketing of their tests.

Rhythm's Chief Commercial Officer, Elena Deak, said "We are excited about the opportunity to collaborate with Nutripath and Tecan to investigate and automate our immunoassay on the Tecan EVO. This brings significant synergies between all three parties and is a substantial step to ensure that we can bring ColoSTAT to market and make it easier to operate for our customers."

Nutripath Director, James Cavaggion, said “we are thrilled to extend our technology services in conjunction with Tecan to support Rhythm Biosciences to establish an automated solution using the Tecan EVO. This marks the initial stage of a promising partnership, with the potential to explore other avenues in the months to come.”

- ENDS -

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investor@rhythmbio.com or on +61 3 8256 2880:

Mr Otto Buttula Executive Chairman	Ms Elena Deak Chief Commercial Officer	Mr Paul Smith CFO & Company Secretary
--	--	---

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and Twitter.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience's simple blood test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood presence of CRC. The test can be used as an alternative for individuals who are unable or unwilling to participate in current screening programs.

The ColoSTAT® Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About Nutripath Pty Ltd

Nutripath is a Melbourne based privately owned medical laboratory, established in 2011. Nutripath is a specialty clinical laboratory, pioneering a systems approach that supports healthcare providers in the area of health and wellbeing pathology testing. Their testing services assist general practitioners and other healthcare providers in identifying the underlying cause of illness, as well as providing tools for the prevention of disease and premature ageing. Nutripath has NATA ISO15189 accreditation, a requirement for quality and competence in medical laboratories.